MAVENCLAD™ (cladribine tablets) │ EMD Serono
We're sorry, but we're unable to process your login. Please try again.
We're sorry, you are not authorized to access this site. Please contact your local Merck KGaA, Darmstadt, Germany representative.
This page requires you to register for an account with Merck KGaA, Darmstadt, Germany.

{* #signInForm *}
{* signInEmailAddress *}
{* currentPassword *}
{* captcha *}
{* /signInForm *}

Safety and tolerability profile


In clinical trials, MAVENCLAD was generally well tolerated1

Tolerability Tolerability

In the 2-year CLARITY EXT*, the safety outcomes were consistent with the safety profile observed in CLARITY.1

Learn more about MAVENCLAD




Patient experience



Discover MAVENCLAD’s monitoring.

Learn more

Understand MAVENCLAD’s MOA.

Learn more

Read about MAVENCLAD’s
patient experience, which is supported
by 4 years of clinical trial experience
and up to 8 years of follow-up experience
with over 10,000 patient-years.2

Learn more

Footnotes and References

ADR=adverse drug reaction; AE=adverse event

 * 96-week extension study to evaluate the safety and efficacy of cladribine tablets in patients with relapse-remitting multiple sclerosis. The primary objective was safety; efficacy endpoints were exploratory. 806 patients, who had completed the CLARITY study received either a cumulative dose of cladribine tablets 3.5 mg/kg or placebo, with blind maintained.1,3

  1. MAVENCLAD™ Product Monograph. EMD Serono. November 2017.
  2. Letter on file. EMD Serono. December 2017.
  3. Giovannoni G, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler 2017 [Epub ahead of print].

You are leaving our website

You are now leaving our website. This link may lead to a resource maintained by third parties over whom we have no control. As such, we are not responsible for and make no representation to the accuracy or any other aspect of such resource or the privacy practices of such third party. Providing links to a third-party website does not constitute an endorsement by our company of such website or the information or products presented on such website.